Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Endocrinology ; 142(4): 1489-96, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11250929

RESUMO

We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system.


Assuntos
Angiotensina II/farmacologia , Comunicação Autócrina/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/biossíntese , Proteínas Musculares/metabolismo , Músculo Esquelético/patologia , Síndrome de Emaciação/induzido quimicamente , Animais , Northern Blotting , Western Blotting , Peso Corporal/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/genética , Fator de Crescimento Insulin-Like I/farmacologia , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Proteínas Musculares/biossíntese , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Ensaios de Proteção de Nucleases , Tamanho do Órgão/efeitos dos fármacos , RNA Mensageiro/biossíntese , Radioimunoensaio , Ratos , Ratos Sprague-Dawley , Síndrome de Emaciação/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA